These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3594958)

  • 1. Antiarrhythmic effects of oral indecainide in patients with ventricular tachyarrhythmias.
    Macina G; Turitto G; Stavens C; Fontaine J; Hariman R; Ursell S; el-Sherif N
    Clin Cardiol; 1987 Jun; 10(6):357-61. PubMed ID: 3594958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardia.
    Pratt CM; Francis MJ; Seals AA; Zoghbi W; Young JB
    Am J Cardiol; 1990 Jul; 66(1):68-74. PubMed ID: 2193498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indecainide for treatment of ventricular ectopic depolarizations: efficacy, pharmacokinetics, hemodynamic effects and safety.
    Salerno DM; Krejci J; Granrud G; Hodges M
    J Am Coll Cardiol; 1988 Apr; 11(4):843-50. PubMed ID: 3351153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of indecainide in patients with left ventricular dysfunction.
    Giardina EV; Saroff AL; Schneider M
    Clin Pharmacol Ther; 1990 Nov; 48(5):582-9. PubMed ID: 2225716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia.
    Podrid PJ; Hohnloser S; Lown B
    Am J Cardiol; 1988 Apr; 61(10):764-9. PubMed ID: 2451415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effects of indecainide in a drug-resistant population with ventricular tachycardia at programmed electrical stimulation.
    Miura DS; Wynn J; Keefe D; Laux B; Somberg JC
    Am Heart J; 1987 Jan; 113(1):65-9. PubMed ID: 3799443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia.
    Platia EV; Estes M; Heine DL; Griffith LS; Garan H; Ruskin JN; Reid PR
    Am J Cardiol; 1985 Apr; 55(8):956-62. PubMed ID: 3984883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical electrophysiology of intravenous indecainide.
    Horowitz LN; Spielman SR; Webb CR; Morganroth J; Greenspan AM
    Am Heart J; 1985 Oct; 110(4):784-8. PubMed ID: 4050649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indecainide compared with quinidine for chronic stable ventricular arrhythmias secondary to coronary artery disease or to cardiomyopathy.
    Giardina EG; Zaim S; Saroff AL; Kirschenbaum M
    Am J Cardiol; 1987 Sep; 60(7):584-9. PubMed ID: 2442993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of acute antiarrhythmic drug efficacy to left ventricular function in coronary artery disease.
    Meissner MD; Kay HR; Horowitz LN; Spielman SR; Greenspan AM; Kutalek SP
    Am J Cardiol; 1988 May; 61(13):1050-5. PubMed ID: 3284319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of oral and intravenous indecainide in ventricular arrhythmias.
    Nestico PF; Morganroth J; Horowitz LN; Mulhern C
    Am J Cardiol; 1987 Jun; 59(15):1332-6. PubMed ID: 3296725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indecainide: effects on arrhythmias, electrophysiology, and cardiovascular dynamics.
    Holland DR; Lacefield WB; Gonzales CR; Johnston SR; Turk JA
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):454-61. PubMed ID: 2476626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New aspects of the clinical use of anti-arrhythmia agents with special reference to acute therapy of ventricular tachycardia (lidocaine vs. ajmaline)].
    Manz M; Mletzko R; Jung W; Lüderitz B
    Herz; 1990 Apr; 15(2):79-89. PubMed ID: 2188894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic effects of cibenzoline.
    Miura DS; Keren G; Torres V; Butler B; Aogaichi K; Somberg JC
    Am Heart J; 1985 Apr; 109(4):827-33. PubMed ID: 3984837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of nadolol alone or in combination with a type IA antiarrhythmic drug in sustained ventricular tachycardia: a prospective study.
    Munsif AN; Saksena S
    Pacing Clin Electrophysiol; 1989 Nov; 12(11):1816-26. PubMed ID: 2478982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia.
    Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN
    Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites.
    Anderson JL; Stewart JR; Johnson TA; Lutz JR; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(5):812-9. PubMed ID: 6182414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease.
    Weintraub AR; Manolis AS; Estes NA
    Am J Cardiol; 1990 Oct; 66(12):947-53. PubMed ID: 2121017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias.
    Browne KF; Prystowsky EN; Zipes DP; Chilson DA; Heger JJ
    J Am Coll Cardiol; 1984 Mar; 3(3):857-64. PubMed ID: 6693656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio.
    Pratt CM; Eaton T; Francis M; Woolbert S; Mahmarian J; Roberts R; Young JB
    Am Heart J; 1989 Sep; 118(3):433-40. PubMed ID: 2476016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.